Pharmacology and mechanisms of apigenin in preventing osteoporosis
Osteoporosis (OP) stands as the most prevalent systemic skeletal condition associated with aging. The current clinical management of OP predominantly depends on anti-resorptive and anabolic agents. Nevertheless, prolonged use of some of these medications has been observed to reduce efficacy and elev...
Saved in:
Main Authors: | Sun Lin, Wang Yincang, Du Jiazhe, Xu Xilin, Xiaofeng Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1486646/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protective effects of apigenin in neurodegeneration: An update on the potential mechanisms
by: Ali Mohammadkhanizadeh, et al.
Published: (2025-03-01) -
Dichotomitin promotes osteoblast differentiation and improves osteoporosis by inhibiting oxidative stress
by: Meichun Han, et al.
Published: (2025-01-01) -
Application of extracellular vesicles in diabetic osteoporosis
by: Xiaopeng Jia, et al.
Published: (2024-12-01) -
Therapeutical properties of apigenin: a review on the experimental evidence and basic mechanisms
by: Zarina Mushtaq, et al.
Published: (2023-09-01) -
The therapeutic potential of apigenin against atherosclerosis
by: Xueqiang Jiang, et al.
Published: (2025-01-01)